Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

CAFC denies Vanderbilt’s claim to Cialis patent right: Vanderbilt University v ICOS Corporation (Patently-O) (IPBiz)

Paris District Court: Basic patent for Losartan covers any product comprising Losartan: Du Pont v Mylan Losartan SPC case (EPLAW)

WHO documents from counterfeit meeting now online (IP Watch)

WHO review of pandemic flu response underway (IP Watch)

Africa: BioPiracy in Africa: Take 2? (Spicy IP)

Argentina: Argentina’s scientific data laws and TRIPs compliance (IP tango)

Chile: Secretary General of International Seed Federation visits Chile, pressures nation to sign UPOV 91 (IP tango)

EU: AHP Manufacturing BV v Bureau voor de Industriële Eigendom analysis now in print (The SPC Blog)

Hungary: Metropolitan Appeal Court: Preliminary injunction refused concerning combination patent (EPLAW)

Hungary: Metropolitan Appeal Court of Budapest upholds decision of Metropolitan Court ordering preliminary injunction against generic drug manufacturer (EPLAW)

India: Open source drug discovery successfully maps TB genome (Spicy IP)

UK: Some thoughts from Fordham on industrial applicability: Eli Lilly v Human Genome Sciences (PatLit)

US: ITC grants Amgen’s motion for partial termination and requests additional briefing in Certain Products Containing Recombinant Human Erythropoietin (ITC 337 Law Blog)

US: CAFC decides claims not indefinite: Enzo Biochem, Inc v Applera Corp (IPBiz) (Patent Docs)

US: Congressman Becerra once again tries to ban gene patenting by statute (Patent Docs)

US: Anti-commons aren’t so tragic – Nature Biotechnology article ‘Empirical analysis of major stem cell patent cases: the role of universities’ (Patent Docs)

US: A disin‘gene’uous lawsuit: ACLU challenges DNA patents (PatentlyBIOtech)

US: Promote Innovation files false marking suit based on Esai’s marking of its Gliadel products (Patent Docs)

Actonel (Risedronate) – US: Warner Chilcott files patent infringement suit against Mylan following Para IV challenge (Patent Docs)

Cialis (Tadalafil) – US: Joint inventorship: CAFC denies Vanderbilt’s claim to Cialis patent right: Vanderbilt University v ICOS Corporation (Patently-O) (IPBiz)

Cozaar, Hyzaar, Fortzaar (Losartan, Hydrochlorothiazide) – France: Paris District Court: Basic patent for Losartan covers any product comprising Losartan: Du Pont v Mylan Losartan SPC case (EPLAW)

Dovonex (Calcipotriene) – US: LEO Pharma files patent infringement complaint against Tolmar in response to Para IV challenge (Patent Docs)

Exelderm (Sulconazole) – US: Promote Innovation files false marking suit against Ranbaxy over marking of Exelderm (Patent Docs)

Famvir (Famciclovir) – US: Novartis files patent infringement complaint against Macleods following Para IV challenge (Patent Docs)

Januvia (Sitagliptin) – EU: Full translation of German Sitagliptin referral to the ECJ now available (The SPC Blog)

Kapidex (Dexlansoprazole) – US: Promote Innovation files false marking suit against Takeda based on patent marking of Kapidex products (Patent Docs)

OxyContin (Oxycodone) – Netherlands: District Court of The Hague rules EP 730 covering controlled release oxycodone formulation is valid and infringed: Mundipharma Pharmaceuticals B.V. v. Sandoz B.V. (EPLAW)

Prevacid (Lansoprazole) – US: Takeda files patent infringement complaint against Zydus following Para IV challenge (Patent Docs)

Reyataz (Atazanavir) – US: Bristol-Myer Squibb, Novartis file patent infringement suit against Teva following Para IV challenge (Patent Docs)

Treximet (Sumatriptan, Naproxen) – US: POZEN enters into settlement agreement with Teva regarding Para IV patent litigation (SmartBrief)

Zerit (Stavudine) – US: Promote Innovation files false marking suit against Bristol-Myers Squibb over marking of Zerit product (Patent Docs)